Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Few chemotherapeutics have had such an impact on cancer management as cis-diamminedichloridoplatinum(II) (CDDP), also known as cisplatin. The first member of the platinum-based drug family, CDDP's potent toxicity in disrupting DNA replication has led to its widespread use in multidrug therapies, with particular benefit in patients with testicular cancers. However, CDDP also produces significant side effects that limit the maximum systemic dose. Various strategies have been developed to address this challenge including encapsulation within micro- or nanocarriers and the use of external stimuli such as ultrasound to promote uptake and release. The aim of this review is to look at these strategies and recent scientific and clinical developments.

Original publication

DOI

10.1021/acsnano.7b04092

Type

Journal article

Journal

Acs nano

Publication Date

26/09/2017

Volume

11

Pages

8560 - 8578

Keywords

CDDP, cisplatin, drug delivery and release, electro-motive force, hyperthermia, magnetic targeting, nanoparticles, ultrasound, Animals, Antineoplastic Agents, Cisplatin, Drug Carriers, Drug Delivery Systems, Humans, Nanoparticles, Neoplasms